Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KPA, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J, Blazar BR. Zaiken MC, et al. Among authors: bluestone ja. Blood. 2022 May 12;139(19):2983-2997. doi: 10.1182/blood.2021014557. Blood. 2022. PMID: 35226736 Free PMC article.
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.
Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA. Huynh A, et al. Among authors: bluestone ja. Nat Immunol. 2015 Feb;16(2):188-96. doi: 10.1038/ni.3077. Epub 2015 Jan 5. Nat Immunol. 2015. PMID: 25559257 Free PMC article.
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M. Wang D, et al. Among authors: bluestone ja. Cell Rep. 2018 Jun 12;23(11):3262-3274. doi: 10.1016/j.celrep.2018.05.050. Cell Rep. 2018. PMID: 29898397 Free PMC article.
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL. Bayless NL, et al. Among authors: bluestone ja. J Immunother Cancer. 2021 Sep;9(9):e002627. doi: 10.1136/jitc-2021-002627. J Immunother Cancer. 2021. PMID: 34479924 Free PMC article. Review.
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, Tang Q. Muller YD, et al. Among authors: bluestone ja. Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021. Front Immunol. 2021. PMID: 34616392 Free PMC article.
535 results